Abstract The antiviral function of type-I interferons (IFN-I) requires activation of multiple signaling components, including the IκB kinase epsilon (IKKɛ). We recently reported that the E3-ubiquitin ligase TRIM6 catalyzes the synthesis of unanchored K48-linked polyubiquitin chains, which are not covalently attached to any protein, and activate IKKɛ for induction of IFN-I mediated antiviral responses. The importance of TRIM6 as an antiviral factor is highlighted by our findings that the highly pathogenic Nipah virus (NiV; Paramyxoviridae family) can inhibit IFN-I responses by targeting TRIM6. To overcome this antiviral pathway, the matrix protein of NiV promotes TRIM6 degradation, resulting in reduced levels of unanchored K48-linked polyubiquitin chains associated with IKKɛ, which in turn leads to impaired IKKɛ activation. In contrast, Ebola virus (EBOV; Filoviridae family), which antagonizes IFN-I responses via its VP35 protein, also hijacks TRIM6 to enhance its own replication, but does it primarily by directly promoting virus replication. Our data show that EBOV-VP35 is ubiquitinated by TRIM6 and promotes VP35-dependent polymerase activity. In line with these results, TRIM6-knockout cell lines and cells derived from our newly generated TRIM6−/− mouse exhibit reduced EBOV replication, even in the absence of IFN-I production. This is the first evidence indicating that TRIM6 represents a major antiviral host factor that is targeted by different viruses to promote their own replication.